pirfenidone has been researched along with losartan in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, J; Chen, Z; Cheng, Z; Hu, G; Jiang, D; Li, Q; Lu, M; Peng, Z; Tao, L; Xiong, X | 1 |
| Aquilina, K; Hobbs, C; Thoresen, M; Tucker, A; Whitelaw, A | 1 |
| Aoudjehane, L; Becquart, J; Bisch, G; Boelle, PY; Calmus, Y; Conti, F; Delelo, R; Housset, C; Paye, F; Scatton, O | 1 |
4 other study(ies) available for pirfenidone and losartan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discovery of 1-(4-((3-(4-methylpiperazin-1-yl)propyl)amino)benzyl)-5-(trifluoromethyl)pyridin-2(1H)-one, an orally active multi-target agent for the treatment of diabetic nephropathy.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Discovery; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Mice; Molecular Structure; NIH 3T3 Cells; Oxidative Stress; Piperazines; Pyridones; Rats; Structure-Activity Relationship | 2018 |
Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebral Ventricles; Dilatation, Pathologic; Disease Models, Animal; Losartan; Pyridones; Random Allocation; Rats; Rats, Wistar; Transforming Growth Factor beta | 2008 |
Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.
Topics: Actins; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cells, Cultured; Collagen Type I; Drug Evaluation, Preclinical; Gene Expression; Humans; In Vitro Techniques; Liver; Liver Cirrhosis; Losartan; Models, Biological; Myofibroblasts; Pyridones | 2016 |